4-chloro-2-[3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol | 637321-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-chloro-2-[3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol
• CAS: 637321-20-1
• 化学式: C₁₆H₁₅ClN₂O
• 分子量: 286.761
• InChiKey: BTOSROOMEFWDKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  44.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-2-[3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol 在 4-二甲氨基吡啶 、 三乙胺 、 potassium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-(5-(5-chloro-2-hydroxy-phenyl)-3-(4-methyl-phenyl)-4,5-dihydro-pyrazol-1-yl)ethanone-2-piperidine
  参考文献：
  名称：

  Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors

  摘要：

  Thirty seven novel 2-pyrazoline-1-ethanone derivatives were designed, synthesized and evaluated as selective hMAO inhibitors. Among them, compounds 7h (IC50 = 2.40 mu M) and 12c (IC50 = 2.00 mu M) exhibited best inhibitory activity and selectivity against hMAO-A, surpassing that of the positive control Clorgyline (IC50 = 2.76 mu M). Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3) > piperidinyl (4) > morpholinyl (5) > imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity. Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively. In addition, the substituent at C3 position of 2-pyrazoline with the N1 acetyl has little effect on MAO-A inhibitory activity. These data support further studies to assess rational design of more efficiently selective hMAO inhibitors in the future. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.010
• 作为产物：
  描述：

  3-(5-chloro-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 4-chloro-2-[3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol
  参考文献：
  名称：

  新型三环吡唑并[1,5- d ] [1,4]苯并a嗪-5（6 H）-one：设计，合成，模型和用作hMAO-B抑制剂

  摘要：

  基于我们最近报道的选择性hMAO-A抑制剂，分子内环化作用导致异构体选择性发生了非常有趣的变化。设计并合成了一系列具有新型三环吡唑并[1,5- d ] [1,4]苯并恶嗪-5（6 H）-支架的选择性hMAO-B抑制剂（3a - 3u）。化合物3u（IC 50  = 221 nM）表现出最佳的抑制活性和对hMAO-B的同工型选择性，优于司来吉兰（IC 50 ＝ 321nM），其是用于帕金森氏病的商业选择性hMAO-B抑制剂。模型研究表明，我们的化合物对hMAO-B的选择性取决于至少两个残基，即Ile 199和Cys 172（或对应于hMAO-A的Phe 208和Asn 181）。这些数据支持进一步的研究，以评估更有效的选择性hMAO-B抑制剂的合理设计。

  DOI：

  10.1016/j.bmc.2016.02.045

文献信息

• Design, synthesis and biological evaluation of tricyclic pyrazolo[1,5-<i>c</i>][1,3]benzoxazin-5(5<i>H</i>)-one scaffolds as selective BuChE inhibitors
  作者：Guo-Liang Qiu、Shao-Sheng He、Shi-Chao Chen、Bo Li、Hui-Hui Wu、Jing Zhang、Wen-Jian Tang

  DOI：10.1080/14756366.2018.1488696

  日期：2018.1.1

  Based on the structural analysis of tricyclic scaffolds as butyrylcholinesterase (BuChE) inhibitors, a series of pyrazolo[1,5-c][1,3]benzoxazin-5(5H)-one derivatives were designed, synthesized and evaluated for their acetylcholinesterase (AChE) and BuChE inhibitory activity. Compounds with 5-carbonyl and 7- or/and 9-halogen substitutions showed potential BuChE inhibitory activity, among which compounds

  基于三环支架作为丁酰胆碱酯酶（BuChE）抑制剂的结构分析，设计，合成了一系列吡唑并[1,5-c] [1,3]苯并恶嗪-5（5H）-one衍生物，并对其乙酰胆碱酯酶进行了评估（ AChE）和BuChE抑制活性。具有5-羰基和7-或/和9-卤素取代基的化合物显示出潜在的BuChE抑制活性，其中化合物6a，6c和6g显示出最佳的BuChE抑制作用（IC50分别为1.06、1.63和1.63 µM）。结构活性关系表明5-羰基和卤素取代基显着影响BuChE活性。发现化合物6a和6g无毒，亲脂并显示出显着的神经保护活性和对BuChE的混合型抑制作用（Ki分别为7.46和3.09 µM）。
• Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors
  作者：Jia-Jia Liu、Hui Zhang、Juan Sun、Zhong-Chang Wang、Yu-Shun Yang、Dong-Dong Li、Fei Zhang、Hai-Bin Gong、Hai-Liang Zhu

  DOI：10.1016/j.bmc.2012.08.020

  日期：2012.10

  A series of novel 4,5-dihydropyrazole derivatives (3a-3t) containing hydroxyphenyl moiety as potential V600E mutant BRAF kinase (BRAF(V600E)) inhibitors were designed and synthesized. Docking simulation was performed to insert compounds 3d (1-(5-(5-chloro-2-hydroxyphenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone) and 3m (1-(3-(4-chlorophenyl)-5-(3,5-dibromo-2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone) into the crystal structure of BRAF(V600E) to determine the probable binding model, respectively. Based on the preliminary results, compound 3d and 3m with potent inhibitory activity in tumor growth may be a potential anticancer agent. Results of the bioassays against BRAF(V600E), MCF-7 human breast cancer cell line and WM266.4 human melanoma cell line all showed several compounds had potent activities IC50 value in low micromolar range, among them, compound 3d and compound 3m showed strong potent anticancer activity, which were proved by that 3d: IC50 = 1.31 mu M for MCF-7 and IC50 = 0.45 mu M for WM266.5, IC50 = 0.22 mu M for BRAF(V600E), 3m: IC50 = 0.97 mu M for MCF-7 and IC50 = 0.72 mu M for WM266.5, IC50 = 0.46 mu M for BRAF(V600E), which were comparable with the positive control Erlotinib. (C) 2012 Elsevier Ltd. All rights reserved.